Yervoy

Active substance

Ipilimumab

Holder

Bristol Myers Squibb (BMS)

Status

Running

Indication

In combination with nivolumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high colorectal cancer in the following settings:

• first-line treatment of unresectable or metastatic colorectal cancer;
• treatment of metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy

Public documents

Approbation

Information for the patient

Informed consent

Last update

17/09/2025